| I-28 Fatemeh Aghai Physiologically-based pharmacokinetic modeling of ruxolitinib and posaconazole to predict the clinically relevant CYP3A4 mediated drug-drug interaction |
| I-29 Laura Ben Olivo Pharmacokinetic modeling based on physiology (PBPK): an innovative strategy for optimization of Piperacillin pharmacotherapy |
| I-30 Pavlos Chrysafidis A paradigm shift in oral drug absorption: The rise of physiologically based finite time pharmacokinetic (PBFTPK) models. |
| I-31 Rebekka Fendt Systematic evaluation of personalized physiologically based pharmacokinetic simulations |
| I-32 Angele Fleury A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol and caffeine |
| I-33 Bart Lammens A Physiologically Based Pharmacokinetic (PBPK) Model of Sildenafil to Predict Exposure in Pregnant Females. What is missing? |
| I-34 Jennifer Lang Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions |
| I-35 Antonina Nikitich Prediction of PD-L1 receptor occupancy in the tumor with PBPK/RO model of PD-L1 inhibitors |
| I-36 Luna Prieto Garcia Simvastatin disposition described by physiologically based pharmacokinetics: Does choice of applied PBPK platform matter? |
| I-37 Javier Reig-López Physiologically Based Pharmacokinetic Model for Atorvastatin: New Insights in Enzymatic and Transport Processes. |
| I-38 Mohammed Saleh Predicting the impact of healthy aging on the brain pharmacokinetic profiles using a translational modeling approach |
| I-39 Ayatallah Saleh Physiologically-based pharmacokinetic (PBPK) modelling to explore the pharmacokinetics (PK) and drug-drug interactions (DDI) potential of midazolam and 1-hydroxymidazolam: the hypothesis of lysosomal trapping |
| I-40 Christina Kovar Physiologically based pharmacokinetic (PBPK) modeling of (E)-clomiphene drug-drug-gene interactions with CYP2D6 and clarithromycin |
| I-41 Jennifer Tardiveau A Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline |
| I-42 Sung-yoon Yang Application of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine. |
